Clinical Research Lead-Oncology
Eli Lilly and CompanyFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Candidates must possess an MD degree or equivalent advanced training in Oncology, with preference given to those with 5 years of clinical research experience in biotechnology/pharmaceutical, clinical research organizations, or academic research settings. Strong analytical and strategic thinking skills, along with goal-oriented and self-motivated characteristics, are required, as well as the ability to work collaboratively in a team environment and lead cross-functional teams. Experience with site engagement and operations in clinical research settings, and familiarity with Good Clinical Practice and relevant regulations, are also necessary.
The Associate Medical Director/Medical Director, Clinical Development will drive clinical development plans for precision medicine products, including genomic assays and algorithmic diagnostics, throughout their lifecycle, encompassing clinical validation and utility studies, and post-market data review. They will provide medical expertise and subspecialty clinical context, design and conduct studies, lead multidisciplinary teams, deliver scientific presentations and publications, and engage in collaborations with external clinical research centers and investigators. Additionally, they will contribute to the development of HR policies to ensure compliance, conduct audits, and advise management on HR-related risk mitigation strategies.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.